Evidence map›Paper›PMID 29560584›Full record

ArticlePharmaceutical research2018

In Vitro TyRP-1 Knockdown Based on siRNA Carried by Liquid Crystalline Nanodispersions: an Alternative Approach for Topical Treatment of Vitiligo.

Larissa Bueno Tofani, Lívia Vieira Depieri, Patrícia Mazureki Campos, Thalita Bachelli Riul, Kamilla Swiech Antonietto, Márcia Carvalho de Abreu Fantini, Maria Vitória Lopes Badra Bentley

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Larissa Bueno TofaniSchool of Pharmaceutical Sciences of Ribeirao Preto, University of Sao Paulo, Avenida do Café, s/n, Ribeirão Preto, SP, 14040-903, Brazil.
Lívia Vieira DepieriSchool of Pharmaceutical Sciences of Ribeirao Preto, University of Sao Paulo, Avenida do Café, s/n, Ribeirão Preto, SP, 14040-903, Brazil.
Patrícia Mazureki CamposSchool of Pharmaceutical Sciences of Ribeirao Preto, University of Sao Paulo, Avenida do Café, s/n, Ribeirão Preto, SP, 14040-903, Brazil.
Thalita Bachelli RiulSchool of Pharmaceutical Sciences of Ribeirao Preto, University of Sao Paulo, Avenida do Café, s/n, Ribeirão Preto, SP, 14040-903, Brazil.
Kamilla Swiech AntoniettoSchool of Pharmaceutical Sciences of Ribeirao Preto, University of Sao Paulo, Avenida do Café, s/n, Ribeirão Preto, SP, 14040-903, Brazil.
Márcia Carvalho de Abreu FantiniPhysics Institute, University of Sao Paulo, São Paulo, Brazil.
Maria Vitória Lopes Badra BentleySchool of Pharmaceutical Sciences of Ribeirao Preto, University of Sao Paulo, Avenida do Café, s/n, Ribeirão Preto, SP, 14040-903, Brazil. vbentley@usp.br.
Universidade de São Paulo · BR

Funding

CNPq Grant # 465687/2014-8FAPESP Grant # 04/09465-7FAPESP grant # 2013/06559-0FAPESP Grant # 2014/50928-2
6 · The paper itself

Abstract

purposeVitiligo is a skin disease characterized by depigmentation and the presence of white patches that are associated with the loss of melanocytes. The most common explanation for the cause of this condition is that it is an autoimmune condition. TyRP-1 is involved in melanin pigment synthesis but can also function as a melanocyte differentiation antigen. This protein plays a role in the autoimmune destruction of melanocytes, which results in the depigmentation, characteristic of this disease. In this study, we evaluated liquid crystalline nanodispersions as non-viral vectors to deliver siRNA-TyRP-1 as an alternative for topical treatment of vitiligo.

methodsLiquid crystalline nanodispersions were obtained and characterized with respect to their physical-chemical parameters including size, PdI and zeta potential, as well as Small Angle X-ray Scattering and complexing to siRNA. The effects of the liquid crystalline nanodispersions on the cellular viability, cell uptake and levels of the knockdown target TyRP-1 were evaluated in melan-A cells after 24 h of treatment.

resultsThe liquid crystalline nanodispersions demonstrated adequate physical-chemical parameters including nanometer size and a PdI below 0.38. These systems promoted a high rate of cell uptake and an impressive TyRP-1 target knockdown (> 80%) associated with suitable loading of TyRp-1 siRNA.

conclusionsWe demonstrated that the liquid crystalline nanodispersions showed promising alternative for the topical treatment of vitiligo due to their physical parameters and ability in knockdown the target protein involved with autoimmune destruction of melanocytes.

Indexed as

Administration, TopicalAnimalsCell LineDrug CarriersDrug Evaluation, PreclinicalGene Knockdown TechniquesGenetic TherapyGenetic VectorsLiquid CrystalsMelanocytesMembrane GlycoproteinsMiceNanoparticlesOxidoreductasesRNA, Small InterferingVitiligoDrug CarriersMembrane GlycoproteinsOxidoreductasesRNA, Small InterferingTyrp1 protein, mousein vitro knockdownliquid crystalline nanodispersionssiRNATyRP-1vitiligo

Identifiers

PMID29560584
OpenAlexW2789567114

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.